Summary Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Net cash flows from operating activities:
Net income	$ 5,863	$ 5,505
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	4,176	3,557
Non-cash compensation	2,251	2,140
Deferred income taxes	1,636	41
Other non-cash adjustments to income	1,054	487
Changes in operating assets and liabilities:
Receivables	(790)	1
Deferred preservation costs and inventories	(1,365)	2,300
Prepaid expenses and other assets	(792)	(968)
Accounts payable, accrued expenses, and other liabilities	(1,025)	644
Net cash flows provided by operating activities	11,008	13,707
Net cash flows from investing activities:
Advances under notes receivable	(1,000)
Capital expenditures	(2,210)	(1,993)
Purchases of restricted securities and investments		(3,569)
Other	(760)	(506)
Net cash flows used in investing activities	(21,010)	(27,130)
Net cash flows from financing activities:
Cash dividends paid	(686)
Proceeds from exercise of stock options and issuance of common stock	302	703
Repurchase of common stock	(3,463)	(1,607)
Other	(74)	(109)
Net cash flows used in financing activities	(3,921)	(1,013)
Decrease in cash and cash equivalents	(13,923)	(14,436)
Effect of exchange rate changes on cash	8	(11)
Cash and cash equivalents, beginning of period	21,705	35,497
Cash and cash equivalents, end of period	7,790	21,050
Hemosphere [Member]
Net cash flows from investing activities:
Acquisition, net of cash acquired	(17,040)
Cardiogenesis [Member]
Net cash flows from investing activities:
Acquisition, net of cash acquired		$ (21,062)